110 related articles for article (PubMed ID: 18443476)
1. Poly(ADP-ribose) polymerase: a new therapeutic target?
Gerö D; Szabó C
Curr Opin Anaesthesiol; 2008 Apr; 21(2):111-21. PubMed ID: 18443476
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Radovits T; Lin LN; Zotkina J; Gero D; Szabó C; Karck M; Szabó G
Eur J Pharmacol; 2007 Jun; 564(1-3):158-66. PubMed ID: 17397824
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Xiao CY; Chen M; Zsengellér Z; Li H; Kiss L; Kollai M; Szabó C
J Pharmacol Exp Ther; 2005 Mar; 312(3):891-8. PubMed ID: 15523000
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Jagtap P; Szabó C
Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite.
Radovits T; Zotkina J; Lin LN; Bömicke T; Arif R; Gerö D; Horváth EM; Karck M; Szabó C; Szabó G
Exp Biol Med (Maywood); 2007 Oct; 232(9):1204-12. PubMed ID: 17895528
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Horvath EM; Szabó C
Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
Sodhi RK; Singh N; Jaggi AS
Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699
[TBL] [Abstract][Full Text] [Related]
9. Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock.
Soriano FG; Nogueira AC; Caldini EG; Lins MH; Teixeira AC; Cappi SB; Lotufo PA; Bernik MM; Zsengellér Z; Chen M; Szabó C
Crit Care Med; 2006 Apr; 34(4):1073-9. PubMed ID: 16484919
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.
Kauppinen TM; Suh SW; Genain CP; Swanson RA
J Neurosci Res; 2005 Jul; 81(2):190-8. PubMed ID: 15931673
[TBL] [Abstract][Full Text] [Related]
11. Toward specific functions of poly(ADP-ribose) polymerase-2.
Yélamos J; Schreiber V; Dantzer F
Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
[TBL] [Abstract][Full Text] [Related]
12. Effect of tempol, a membrane-permeable radical scavenger, on mesenteric blood flow and organ injury in a murine cecal ligation and puncture model of septic shock.
Yuksel BC; Serdar SE; Tuncel A; Uzum N; Ataoglu O; Atan A; Hengirmen S; Iskit AB; Guc MO
Eur Surg Res; 2009; 43(2):219-27. PubMed ID: 19556798
[TBL] [Abstract][Full Text] [Related]
13. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
14. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
[TBL] [Abstract][Full Text] [Related]
15. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
16. Establishment of an immortalized PARP-1-/- murine endothelial cell line: a new tool to study PARP-1 mediated endothelial cell dysfunction.
Carrillo A; Monreal Y; Ramirez P; Suarez E; Parrilla P; Menissier-de Murcia J; de Murcia G; Alvarez-Vallina L; Yélamos J
J Cell Biochem; 2005 Apr; 94(6):1163-74. PubMed ID: 15696577
[TBL] [Abstract][Full Text] [Related]
17. Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic endothelial cells.
Mahrouf-Yorgov M; Marie N; Borderie D; Djelidi R; Bonnefont-Rousselot D; Legrand A; Beaudeux JL; Peynet J
Metabolism; 2009 Apr; 58(4):525-33. PubMed ID: 19303974
[TBL] [Abstract][Full Text] [Related]
18. Effect of oxidative stress and involvement of poly(ADP-ribose) polymerase (PARP) in Dictyostelium discoideum development.
Rajawat J; Vohra I; Mir HA; Gohel D; Begum R
FEBS J; 2007 Nov; 274(21):5611-8. PubMed ID: 17922841
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) makes a date with death.
Heeres JT; Hergenrother PJ
Curr Opin Chem Biol; 2007 Dec; 11(6):644-53. PubMed ID: 17936669
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury.
Mota RA; Hernández-Espinosa D; Galbis-Martinez L; Ordoñez A; Miñano A; Parrilla P; Vicente V; Corral J; Yélamos J
Crit Care Med; 2008 Feb; 36(2):526-34. PubMed ID: 18091544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
